ELOXX PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $142.00 thousand for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-09-11
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $142.00K S-1 · filed 2026-09-11 | $142.00M 10-K · filed 2026-03-17 |
| 2024-12-31 | $280.00K S-1 · filed 2026-09-11 | $280.00M 10-K · filed 2026-03-17 |
| 2023-12-31 | $3.43M S-1 · filed 2026-09-11 | $3.43B 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |